Published in J Thorac Oncol on March 01, 2008
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev (2008) 1.32
Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer (2011) 1.17
Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol (2014) 1.13
The enhancement of radiosensitivity in human esophageal squamous cell carcinoma cells by zoledronic acid and its potential mechanism. Cytotechnology (2013) 0.97
Prediction of skeletal-related events in patients with non-small cell lung cancer. Support Care Cancer (2016) 0.96
Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer (2012) 0.94
The importance of multidisciplinary team management of patients with non-small-cell lung cancer. Curr Oncol (2012) 0.91
Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292. Clin Exp Metastasis (2011) 0.90
Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Eur J Cancer (2013) 0.87
Targeted treatments of bone metastases in patients with lung cancer. Front Oncol (2014) 0.85
Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations. Int J Mol Sci (2013) 0.84
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer. Int J Clin Oncol (2011) 0.83
Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group. Cancer Sci (2014) 0.83
Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer (2011) 0.81
Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity? BMC Cancer (2014) 0.80
Remarkable regression of an osteolytic lesion of large cell lung cancer treated with zoledronic Acid: a case report. Case Rep Oncol (2012) 0.79
Bone-targeted agents in the treatment of lung cancer. Ther Adv Med Oncol (2015) 0.78
N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases. Int J Clin Oncol (2010) 0.78
Promising targets and current clinical trials in metastatic squamous cell lung cancer. Front Oncol (2014) 0.78
Optimizing the management of advanced non-small-cell lung cancer: a personal view. Curr Oncol (2009) 0.78
Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status. Int J Cancer (2015) 0.77
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study. Oncotarget (2016) 0.77
Incidence and consequences of bone metastases in lung cancer patients. J Bone Oncol (2013) 0.77
Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases. Sci Rep (2017) 0.75
Diagnostic and prognostic validity of serum bone turnover markers in bone metastatic non-small cell lung cancer patients. J Bone Oncol (2015) 0.75
Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. J Bone Oncol (2013) 0.75
Current perspectives on skeletal health and cancer progression across the disease continuum in breast cancer-the role of bisphosphonates. Ecancermedicalscience (2012) 0.75
Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways. BMB Rep (2017) 0.75
Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort. J Cancer (2016) 0.75
Progress in the research on the mechanism of bone metastasis in lung cancer. Mol Clin Oncol (2016) 0.75
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity: a novel molecular mechanism. J Thorac Oncol (2008) 0.75
Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. Clin Chem (2016) 0.75
Bone metastases in patients with small cell lung carcinoma: rate of development, early versus late onset, modality of treatment, and their impact on survival. A single-institution retrospective cohort study. Clin Exp Metastasis (2016) 0.75
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 10.41
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol (2006) 8.58
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst (2011) 5.79
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol (2008) 3.83
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol (2003) 3.73
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol (2009) 3.37
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope (2006) 3.20
Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol (2014) 3.17
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med (2007) 2.97
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76
Retracted Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol (2009) 2.75
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol (2009) 2.73
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol (2008) 2.68
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol (2002) 2.55
Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer (2007) 2.55
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev (2008) 2.48
Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion (2003) 2.48
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol (2008) 2.20
Risk factors for hip fracture in older home care clients. J Gerontol A Biol Sci Med Sci (2009) 2.15
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res (2010) 2.15
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int (2005) 2.11
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol (2004) 2.02
ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lung. Int J Radiat Oncol Biol Phys (2010) 2.00
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res (2006) 1.99
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol (2008) 1.99
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
Management of complications of prostate cancer treatment. CA Cancer J Clin (2008) 1.91
Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst (2008) 1.87
Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol (2009) 1.86
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol (2008) 1.79
Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer (2005) 1.72
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer (2004) 1.69
Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 1.68
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer (2004) 1.68
Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology (2004) 1.67
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res (2008) 1.67
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol (2010) 1.66
Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 1.66
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer (2003) 1.65
Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol (2012) 1.65
Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol (2012) 1.64
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res (2011) 1.64
Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer (2004) 1.64
National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck (2009) 1.64
Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res (2004) 1.63
Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? Breast Cancer Res Treat (2010) 1.62
Treatment and prevention of bone complications from prostate cancer. Bone (2010) 1.60
Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study. Cancer (2010) 1.59
Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int (2008) 1.59
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol (2013) 1.59
Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer (2008) 1.57
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist (2013) 1.54
Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2014) 1.53
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
Reliability of electrocardiogram interpretation in critically ill patients. Crit Care Med (2006) 1.51
Retracted Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res (2010) 1.51
External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Haemost (2014) 1.49
Clinical decisions. Screening for prostate cancer. N Engl J Med (2012) 1.49
Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol (2013) 1.48
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res (2009) 1.47
The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood (2013) 1.44
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer (2003) 1.43
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood (2005) 1.43
Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? BJU Int (2010) 1.40
Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol (2011) 1.40
Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol (2009) 1.40
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol (2009) 1.39
Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev (2011) 1.39
Statistical methods for multivariate interval-censored recurrent events. Stat Med (2005) 1.38